Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Denis M. Collins(Dublin City University), John Crown(St. Vincent's University Hospital)
Cited by 75
Related Papers
MYC as a target for cancer treatment
|Cancer Treatment Reviews|2021|528
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
|PLoS ONE|2017|54
Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
|International Journal of Oncology|2015|20
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
|British Journal of Cancer|2023|12